在复发性多发性硬化症中使用ocrelizumab的实际有效性:MSBase注册表子研究
Helmut Butzkueven1, Pamela Farr2, Serkan Ozakbas3
1Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia; MSBase Foundation, Alfred Centre, Melbourne, Australia.
Multiple sclerosis and related disorders
|December 20, 2025
概括
在现实环境中,ocrelizumab (OCR) 在复发性多发性硬化症 (RMS) 患者中显示出显著的长期有效性. 该研究观察到复发和残疾进展减少,治疗持久性高.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 奥克雷利祖马布 (OCR) 是一种针对复发性多发性硬化症 (RMS) 的向疗法.
- 现实世界的数据对于了解临床试验之外的长期治疗有效性至关重要.
研究的目的:
- 评估ocrelizumab (OCR) 在现实世界复发性多发性硬化症 (RMS) 患者队列中的长期有效性和安全性.
- 评估结果,包括残疾恶化,疾病进展和没有疾病活性证据 (NEDA-3).
主要方法:
- 使用国际MSBase注册表进行前性,纵向性,观察性队列研究 (MSOCR-R).
- 包括1011名RMS患者,他们刚接受OCR治疗.
- 分析确认的残疾恶化 (CDW),不依赖复发的进展 (PIRA) 和NEDA-3在3.4年的中位随访期间.
主要成果:
- 24周CDW和PIRA的四年概率分别为25.2%和21.9%.
- 年化复发率显著下降,从OCR启动后的0.58降至0.05.
- 在4年内实现NEDA-3的比率为39.7%,治疗持续率为88.0%.
结论:
- 奥克雷利祖马布在治疗复发性多发性硬化症方面表现出强大的现实世界的有效性.
- 使用OCR的第一线治疗与优异的临床结果有关.
- 这些发现支持OCR作为RMS患者有价值的治疗选择.
相关概念视频
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Bioavailability Study Design: Healthy Subjects Versus Patients
133
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
133
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
Bioavailability Study Design: Single Versus Multiple Dose Studies
179
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
179
Bioavailability Study Design: Absolute Versus Relative Bioavailability
267
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
267


